SDZNY
Sandoz Group AG
OTC Markets OTCQXUSDEQUITY
DELAYED
Last price
92.08
▲ 0.55 (0.60%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
91.90
Prev close
91.53
Day high
92.59
Day low
91.30
Volume
2.80K
Market cap
—
P/E (TTM)
—
52W range
55.42 – 94.15
Day trading desk
Gap from prior close
+0.40%
Prior close 91.53
VWAP
92.06
+0.02% from price
Relative volume
—
—
Session range
1.41%
91.30 – 92.59
Position in range
60%
Mid range
ATR (14D)
2.50
2.71% of price
Prior day high
92.63
PDH
Prior day low
91.44
PDL
Bid / ask spread
—
Quote not published
Session volume
2.79K
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.53%
+3.9%
1M
+16.44%
+12.7%
3M
+10.30%
+7.2%
6M
+6.65%
-4.4%
YTD
+26.53%
+14.2%
1Y
+51.57%
+31.6%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on SDZNY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $11.16B | $10.38B | $9.98B | $9.31B | +7.4% |
| Operating revenue | $11.16B | $10.38B | $9.98B | $9.31B | +7.4% |
| Cost of revenue | $5.87B | $5.46B | $5.42B | $4.93B | +7.6% |
| Gross profit | $5.28B | $4.93B | $4.56B | $4.38B | +7.3% |
| Research & development | $1.05B | $932.00M | $926.00M | $833.00M | +12.7% |
| Selling, general & admin | $2.53B | $2.43B | $2.39B | $2.13B | +3.9% |
| Total operating expense | $3.86B | $4.62B | $4.19B | $3.14B | -16.5% |
| Operating income | $1.43B | $307.00M | $375.00M | $1.24B | +364.2% |
| Net interest income | -$216.00M | -$230.00M | -$174.00M | -$87.00M | +6.1% |
| Pre-tax income | $1.21B | -$11.00M | $130.00M | $1.10B | +11,072.7% |
| Tax provision | $293.00M | -$12.00M | $50.00M | $252.00M | +2,541.7% |
| Net income | $914.00M | $0 | $77.00M | $848.00M | — |
| Net income to common | $914.00M | $0 | $77.00M | $848.00M | — |
| Basic EPS | — | 0.00 | 0.18 | 1.97 | — |
| Diluted EPS | — | 0.00 | 0.18 | 1.97 | — |
| EBIT | $1.43B | $240.00M | $332.00M | $1.19B | +494.6% |
| EBITDA | $1.97B | $742.00M | $857.00M | $1.68B | +165.8% |
| Basic shares | — | 430.20M | 429.90M | 431.00M | — |
| Diluted shares | — | 434.00M | 431.20M | 431.00M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.74B | $1.19B | $1.11B | $74.00M | +46.0% |
| Cash & short-term investments | $1.74B | $1.19B | $1.11B | $74.00M | +46.0% |
| Accounts receivable | $2.51B | $2.21B | $2.62B | $2.21B | +13.7% |
| Inventory | $2.85B | $2.80B | $2.70B | $2.12B | +1.6% |
| Total current assets | $8.16B | $7.80B | $7.57B | $5.98B | +4.7% |
| Property, plant & equipment | $2.78B | $1.99B | $1.85B | $1.90B | +39.8% |
| Goodwill & intangibles | $9.88B | $8.94B | $9.15B | $8.89B | +10.5% |
| Total assets | $22.03B | $19.91B | $19.43B | $17.56B | +10.7% |
| Total current liabilities | $6.89B | $6.31B | $5.70B | $7.91B | +9.3% |
| Current debt | $603.00M | $129.00M | $269.00M | $184.00M | +367.4% |
| Long-term debt | $4.70B | $4.39B | $3.98B | $30.00M | +6.9% |
| Total debt | $5.68B | $4.85B | $4.55B | $333.00M | +17.1% |
| Total liabilities | $12.65B | $11.74B | $10.78B | $8.80B | +7.7% |
| Retained earnings | — | — | — | -$22.86K | — |
| Shareholder equity | $9.38B | $8.16B | $8.64B | $8.75B | +15.0% |
| Working capital | $1.27B | $1.49B | $1.87B | -$1.94B | -15.0% |
| Net tangible assets | -$497.00M | -$781.00M | -$506.00M | -$143.00M | +36.4% |
| Shares issued | 440.00M | 440.00M | 431.00M | 431.00M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $914.00M | $1.00M | $80.00M | $850.00M | +91,300.0% |
| Depreciation & amortisation | $545.00M | $502.00M | $525.00M | $492.00M | +8.6% |
| Stock-based compensation | $102.00M | $88.00M | $25.00M | $0 | +15.9% |
| Change in working capital | $863.00M | -$365.00M | -$663.00M | -$36.00M | +336.4% |
| Operating cash flow | $1.59B | $656.00M | $362.00M | $1.22B | +143.0% |
| Capital expenditure | -$784.00M | -$596.00M | -$625.00M | -$427.00M | -31.5% |
| Investing cash flow | -$980.00M | -$740.00M | -$614.00M | -$430.00M | -32.4% |
| Share buybacks | $0 | -$12.00M | $0 | — | +100.0% |
| Dividends paid | -$315.00M | -$215.00M | — | — | -46.5% |
| Financing cash flow | -$197.00M | $242.00M | $1.24B | -$769.00M | -181.4% |
| Free cash flow | $810.00M | $60.00M | -$263.00M | $796.00M | +1,250.0% |
| End cash position | $1.74B | $1.19B | $1.11B | $74.00M | +46.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $1.74B | $1.39B | $1.19B | +25.2% |
| Cash & short-term investments | $1.74B | $1.39B | $1.19B | +25.2% |
| Accounts receivable | $2.51B | $2.31B | $2.21B | +8.4% |
| Inventory | $2.85B | $3.08B | $2.80B | -7.5% |
| Total current assets | $8.16B | $8.37B | $7.80B | -2.5% |
| Property, plant & equipment | $2.78B | $2.33B | $1.99B | +19.3% |
| Goodwill & intangibles | $9.88B | $9.66B | $8.94B | +2.3% |
| Total assets | $22.03B | $21.61B | $19.91B | +1.9% |
| Total current liabilities | $6.89B | $6.48B | $6.31B | +6.5% |
| Current debt | $603.00M | $125.00M | $129.00M | +382.4% |
| Long-term debt | $4.70B | $5.20B | $4.39B | -9.7% |
| Total debt | $5.68B | $5.69B | $4.85B | -0.2% |
| Total liabilities | $12.65B | $12.79B | $11.74B | -1.1% |
| Shareholder equity | $9.38B | $8.82B | $8.16B | +6.4% |
| Working capital | $1.27B | $1.90B | $1.49B | -33.1% |
| Net tangible assets | -$497.00M | -$841.00M | -$781.00M | +40.9% |
| Shares issued | 440.00M | 430.70M | 440.00M | +2.2% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
90.65
+1.58% from price
SMA 20
86.46
+6.50% from price
SMA 50
85.31
+7.93% from price
SMA 100
83.96
+9.67% from price
SMA 200
80.19
+14.83% from price
EMA 12
89.63
+2.73% from price
EMA 26
87.12
+5.69% from price
EMA 50
85.54
+7.65% from price
RSI (14)
62.0
Neutral
MACD (12,26,9)
2.51
Hist 0.66
ATR (14)
2.50
2.71% of price
Realised vol 30D
39.5%
Annualised
Bollinger upper
96.37
20, 2σ
Bollinger lower
76.56
20, 2σ
50 / 200 cross
Golden
85.31 vs 80.19
Trend bias
Above 200
+14.83%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.68
Less volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
39.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-19.1%
Peak to trough
Max drawdown 5Y
-25.3%
Peak to trough
ATR 14
2.50
2.71% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
AstraZeneca scores in lung cancer; Sandoz inks a China deal
BioPharma Dive · 6d ago
Health Care Roundup: Market Talk
The Wall Street Journal · 6d ago
Sandoz targets industry patent void with $322m Henlius deal
Pharmaceutical Technology · 7d ago
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
PR Newswire · 7d ago
Sandoz Group AG (SDZNY) (H1 2026) Earnings Call Highlights: Biosimilar Growth Drives 5% Sales ...
GuruFocus.com · 18d ago
Sandoz in Talks With U.S. Government About Potential Investment, CEO Says
The Wall Street Journal · 18d ago
Sandoz Shares Climb After Biosimilar Sales Drive Growth
The Wall Street Journal · 19d ago
Sandoz Group (SWX:SDZ) Settles US Drug Pricing Cases And Wins Brazil Semaglutide Approval
Simply Wall St. · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.